New Guidelines for HER2-Negative Advanced Breast Cancer — Physician’s First Watch
New Guidelines for HER2-Negative Advanced Breast Cancer
By Kelly Young
The American Society of Clinical Oncology has released new guidelines on managing advanced human epidermal growth factor receptor (HER2)-negative breast cancer. Among the recommendations:
For most patients with hormone-receptor-positive advanced breast cancer, endocrine treatment should be the first-line therapy.
Sequential single-agent chemotherapy regimens should be offered, but combination treatments may be given if the disease is immediately life-threatening.
The use of bevacizumab is controversial given that it improves treatment response but not overall survival when added to single-agent chemotherapy.
For first-line chemotherapy, taxanes and anthracyclines have the strongest evidence for efficacy.
Chemotherapy should not at this time be targeted to specific cancer subtypes.